SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIB
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.
SAB Biotherapeutics vs. Its Competitors
SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
SAB Biotherapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.
SAB Biotherapeutics currently has a consensus price target of $13.25, indicating a potential upside of 640.22%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 1,079.78%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than SAB Biotherapeutics.
SAB Biotherapeutics has a net margin of 0.00% compared to Fortress Biotech's net margin of -71.24%. SAB Biotherapeutics' return on equity of -105.14% beat Fortress Biotech's return on equity.
7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 27.8% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 27.9% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Fortress Biotech received 295 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 84.62% of users gave SAB Biotherapeutics an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.
In the previous week, Fortress Biotech had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Fortress Biotech and 0 mentions for SAB Biotherapeutics. Fortress Biotech's average media sentiment score of 0.33 beat SAB Biotherapeutics' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media.
SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Fortress Biotech beats SAB Biotherapeutics on 10 of the 16 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SABS) was last updated on 6/22/2025 by MarketBeat.com Staff
